Vasomune Therapeutics and AnGes entered a global Co-Development Agreement

| By | Drug Development, R&D

Vasomune Therapeutics (Canada), a Toronto-based spin-out from Sunnybrook Research Institute and MaRS Innovation, and AnGes, Inc. (Japan), a Tokyo-based biotechnology company focused on developing biotherapeutics, announced the signing of an innovative global Co-Development Agreement for the development and commercialization of therapeutics treating diseases associated with blood vessel dysfunction and destabilization.

The collaboration is designed to advance Vasomune’s peptide-based Tie2 receptor agonist program, initially for the treatment of critical care indications, including Acute Respiratory Distress Syndrome (ARDS), into clinical development. ARDS is a critical care indication with a significant unmet medical need as there are currently no approved therapeutics. The parties expect to initiate clinical trials in 2020. With such a foundational mechanism involved in multiple disease states, the parties have the option to co-develop the compounds for additional indications associated with vascular dysfunction and leakage. These indications include asthma, atopic dermatitis, glaucoma and vascular complications of diabetes.

Under the terms of the agreement, AnGes will provide Vasomune with multi-million dollar co-development contributions including upfront and clinical milestone fees. The initial objective of the partnership is to achieve human proof of concept in ARDS, which alone is potentially a $2.5 billion market opportunity worldwide.

AnGes is a biopharmaceutical company focused on the development and commercialization of gene-based medicines including gene therapy and oligonucleotide medicines. The company’s lead product candidate is HGF gene therapy for critical limb ischemia (CLI), for which the application for marketing approval is currently under review by the Japanese authority.

Vasomune Therapeutics is a private biotechnology company developing therapies to target diseases associated with blood vessel (vascular) dysfunction and destabilization. The company’s lead compound is a Tie2 receptor agonist that has demonstrated positive therapeutic effect in many diseases associated with vascular dysfunction. Vasomune Therapeutics is based on research from Sunnybrook Research Institute and was spun out in collaboration with MaRS Innovation with both Sunnybrook Research Institute and MaRS Innovation as founding investors.

SOURCE: globenewswire
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.